Protocol Ledger

NCT03474679 · Phase III · COMPLETED

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

Interventional Phase III clinical trial protocol NCT03474679 sponsored by Johnson & Johnson / Janssen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-01 Enrollment: 19 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03474679
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)19 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03474679
Protocol FieldVerified Registry Value
NCT IdentifierNCT03474679
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment19 participants (ACTUAL)
Registered Start Date2018-05-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03474679
Hospital Research SiteLocationSite Profile
Kobe City Medical Center General HospitalKobe, JapanOpen Hospital Dossier ->
Okayama University HospitalOkayama, JapanOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI